NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Enanta Pharmaceuticals Inc. ENTA
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$65.3M
▼ 3.4% vs FY2024
EPS · FY25
$-3.84
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-84.6%
Net margin · FY25
-125.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 65.3M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 125 cents on every revenue dollar this year.
Per share
USD -3.84
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-84.6%
Return on equity, FY2025
ROE
Operating margin-130.7%
Net margin-125.4%
Return on assets-24.9%
Each USD of equity lost 85 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−11.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−8.8%
−11.8%
−8.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+6.5%
Change, 10 years+14.3%
The share count grew 7% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 280.7M
total assets, end of FY2025
Total assetsUSD 280.7M
EquityUSD 64.7M
CashUSD 32.3M
Current ratio4.21×
Equity funds 23% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.2
0.1
0.1
0.2
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.0
EPS, diluted $
−3.84
−5.48
−6.38
−5.91
−3.92
−1.81
2.21
3.48
0.91
1.13
4.09
1.80
−0.67
1.13
1.32
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−84.6
−67.2
−49.7
−33.8
−18.5
−7.9
10.8
20.7
6.2
8.6
41.1
26.6
·
·
·
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed